The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Noninvasive brain stimulation in Alzheimer's disease: Systematic review and perspectives for the future
Open accessAbstract
Background A number of studies have applied transcranial magnetic stimulation (TMS) to physiologically characterize Alzheimer’s disease (AD) and to monitor effects of pharmacological agents, while others have begun to therapeutically use TMS and transcranial direct current stimulation (tDCS) to improve cognitive function in AD. These applications are still very early in development, but offer the opportunity of learning from them for future development. Methods We performed a systematic search of all studies using noninvasive stimulation in AD and reviewed all 29 identified articles. Twenty-four focused on measures of motor cortical reactivity and (local) plasticity and functional connectivity, with eight of these studies assessing also effects of pharmacological agents. Five studies focused on the enhancement of cognitive function in AD. Results Short-latency afferent inhibition (SAI) and resting motor threshold are significantly reduced in AD patients as compared to healthy elders. Results on other measures of cortical reactivity, e.g. intracortical inhibition (ICI), are more divergent. Acetylcholine-esterase inhibitors and dopaminergic drugs may increase SAI and ICI in AD. Motor cortical plasticity and connectivity are impaired in AD. TMS/tDCS can induce acute and short-duration beneficial effects on cognitive function, but the therapeutic clinical significance in AD is unclear. Safety of TMS/tDCS is supported by studies to date. Conclusions TMS/tDCS appears safe in AD, but longer-term risks have been insufficiently considered. TMS holds promise as a physiologic biomarker in AD to identify therapeutic targets and monitor pharmacologic effects. In addition, TMS/tDCS may have therapeutic utility in AD, though the evidence is still very preliminary and cautious interpretation is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 2×
“Apolipoprotein E (APOE) and its ε4 allele are thought to raise the risk of AD (Corder et al., 1993) in a dose-dependent manner (Bertram et al., 2007), and may also influence brain responses to TMS measures.”
BackgroundNitsche, M. A., & Paulus, W. (2000) · The Journal of Physiology · doi:10.1111/j.1469-7793.2000.t01-1-00633.x · Cited by 5,656
Rossi, S., Hallett, M., Rossini, P. M., & Pascual-Leone, A. (2009) · Clinical Neurophysiology · doi:10.1016/j.clinph.2009.08.016 · Cited by 5,367
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · cited 2×
“It has long been suggested that the pathogenesis of AD may involve deficits in the cholinergic circuits (Davies and Maloney, 1976; Coyle et al., 1983), and agents that enhance cholinergic neurotransmission – e.g., acetylcholine-esterase inhibitors (AChEIs) – are associated with improvements in…”
BackgroundMemory deficits associated with senescence: A neurophysiological and behavioral study in the rat.
Barnes, C. A. (1979) · Journal of Comparative and Physiological Psychology · doi:10.1037/h0077579 · Cited by 2,088
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 2×
“Apolipoprotein E (APOE) and its ε4 allele are thought to raise the risk of AD (Corder et al., 1993) in a dose-dependent manner (Bertram et al., 2007), and may also influence brain responses to TMS measures.”
Background
Cited by
Pascual-Leone, A., Freitas, C., Oberman, L., Horvath, J. C., Halko, M., Eldaief, M., Bashir, S., Vernet, M., Shafi, M., Westover, B., et al. (2011) · Brain Topography · doi:10.1007/s10548-011-0196-8 · Cited by 388
Self-citationComputational Models of Transcranial Direct Current Stimulation
Bikson, M., Rahman, A., & Datta, A. (2012) · Clinical EEG and Neuroscience · doi:10.1177/1550059412445138 · Cited by 283
Changing Brain Networks Through Non-invasive Neuromodulation
To, W. T., De Ridder, D., Hart Jr., J., & Vanneste, S. (2018) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2018.00128 · Cited by 135
“…substance abuse, addiction and craving, amongst others (e.g., Fregni et al., 2008; Benninger et al., 2010; Van den Eynde et al., 2010; Zyss, 2010; Freitas et al., 2011; Avenanti et al., 2012; Borckardt et al., 2012; Brunelin et al., 2012; Frontiers in Human Neuroscience | www.frontiersin.org 1…”
BackgroundNon-pharmacological intervention for memory decline
Cotelli, M., Manenti, R., Zanetti, O., & Miniussi, C. (2012) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2012.00046 · Cited by 76
Metadata
- Authors
- Freitas, C., Mondragón-Llorca, H., & Pascual-Leone, A.
- Venue
- Experimental Gerontology
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 46
- Issue
- 8
- Pages
- 611-27
- ISSN
- 0531-5565 (ISSN-L)
- OpenAlex
- W1993900447
- Cited by
- 161
- References
- 27
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.